Press Enter to search · Esc to close
A new class of generative models is treating peptide design like a search problem — and the early outputs hint at a faster, more targeted pipeline behind a quarter of all pharma.
Three recent papers show machine learning moving from hype to workflow in peptide therapeutics — compressing discovery cycles and flagging safety risks earlier. Here's what changes for a field bottlenecked by synthesis and red-cell toxicity.
Aging research is consolidating. A new wave of papers reframes the field around drug-targetable biology — and it could change what 'anti-aging' actually means.